Dr. Vogl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Civic Center Boulevard
Perelman Center 2 West
Philadelphia, PA 19104Phone+1 215-615-6508Fax+1 215-615-5887- Is this information wrong?
Education & Training
University of Pennsylvania Perelman School of MedicineMSCE, Clinical Trials Methodology, 2009
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
Weill Cornell MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2023 - Present
NJ State Medical License 2022 - 2025
PA State Medical License 2003 - 2024
NY State Medical License 2001 - 2003- American Board of Internal Medicine Hematology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Sep 08
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
- Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine Start of enrollment: 2011 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsExploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.Yan Tang, Wei Liu, Siddhant Kadu, Omar Johnson, Zainul S Hasanali, Andre Kelly, Alexander Shestov, Raymone Pajarillo, Eli Greenblatt, Matthew Holmes, Li-Ping Wang, Nat...> ;Blood. 2024 Jan 11
- 2 citationsS100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.Cindy Lin, Laura Garcia-Gerique, Erin E Bonner, Jerome Mastio, Matthew Rosenwasser, Zachary Cruz, Michael Lawler, Luca Bernabei, Kar Muthumani, Qin Liu, Mortimer Poncz...> ;Cancer Research Communications. 2023 Mar 1
- 2 citationsProgressive multifocal leukoencephalopathy in multiple myeloma.Brian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, Sandra P Susanibar-Adaniya, Dan T Vogl, Adam J Waxman, Mark Bardsley, Samantha Le, Lexis LaMaestra, Alfred L Garfall> ;European Journal of Haematology. 2023 Mar 1
- Join now to see all
Journal Articles
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care WorkersMatthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
Abstracts/Posters
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM StudyDan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple MyelomaDan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual MeetingSeptember 14th, 2018
Novel Agents, Combos Excite in Multiple MyelomaNovember 28th, 2017- Join now to see all
Hospital Affiliations
Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
